Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - emtricitabine, quantity: 200 mg; efavirenz, quantity: 600 mg; tenofovir disoproxil maleate, quantity: 300 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium metabisulfite; hyprolose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; ferric oxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - tenofovir disoproxil/ emtricitabine/ efavirenz mylan 300/200/600 is indicated for the treatment of hiv infected adults over the age of 18 years.,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts in controlled studies of viread, emtriva and stocrin in treatment-na?ve and treatment experienced adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pc holdings pty limited - phentermine hydrochloride, quantity: 49.7 mg - tablet, modified release - excipient ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350; brilliant scarlet 4r aluminium lake - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater.,the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pc holdings pty limited - phentermine hydrochloride, quantity: 37.275 mg - tablet, modified release - excipient ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater.,the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pc holdings pty limited - phentermine hydrochloride, quantity: 18.6375 mg - tablet, modified release - excipient ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; iron oxide yellow; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350 - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater.,the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - eletriptan hydrobromide, quantity: 48.485 mg (equivalent: eletriptan, qty 40 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; sunset yellow fcf; triacetin - for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms.

Canada - English - Health Canada

novartis pharmaceuticals canada inc - ergotamine tartrate; caffeine - tablet - 1mg; 100mg - ergotamine tartrate 1mg; caffeine 100mg - sympatholytic (adrenergic blocking) agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance pharmaceuticals ltd - ergotamine tartrate; caffeine - oral tablet - 1mg ; 100mg

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

jaffar pharmacy - caffeine, ergotamine tartrate - tablet

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - ergotamine tartrate caffeine - tablets - 1 milligram

Canada - English - Health Canada

novartis pharmaceuticals canada inc - pentobarbital sodium; ergotamine (ergotamine tartrate); caffeine; belladonna - tablet - 30mg; 1mg; 100mg; 0.125mg - pentobarbital sodium 30mg; ergotamine (ergotamine tartrate) 1mg; caffeine 100mg; belladonna 0.125mg - sympatholytic (adrenergic blocking) agents